| Cholangiocarcinoma N Razumilava, GJ Gores The Lancet 383 (9935), 2168-2179, 2014 | 1735 | 2014 |
| Cholangiocarcinomas can originate from hepatocytes in mice B Fan, Y Malato, DF Calvisi, S Naqvi, N Razumilava, S Ribback, GJ Gores, ... The Journal of clinical investigation 122 (8), 2911-2915, 2012 | 530 | 2012 |
| Classification, diagnosis, and management of cholangiocarcinoma N Razumilava, GJ Gores Clinical gastroenterology and hepatology 11 (1), 13-21. e1, 2013 | 373 | 2013 |
| Inflammation and liver cancer: molecular mechanisms and therapeutic targets YM Yang, SY Kim, E Seki Seminars in liver disease 39 (01), 026-042, 2019 | 339 | 2019 |
| Cancer surveillance in patients with primary sclerosing cholangitis N Razumilava, GJ Gores, KD Lindor Hepatology 54 (5), 1842-1852, 2011 | 331 | 2011 |
| miR‐25 targets TNF‐related apoptosis inducing ligand (TRAIL) death receptor‐4 and promotes apoptosis resistance in cholangiocarcinoma N Razumilava, SF Bronk, RL Smoot, CD Fingas, NW Werneburg, ... Hepatology 55 (2), 465-475, 2012 | 225 | 2012 |
| Efficacy and safety of endoscopic radiofrequency ablation for unresectable extrahepatic cholangiocarcinoma: a randomized trial J Yang, J Wang, H Zhou, Y Zhou, Y Wang, H Jin, Q Lou, X Zhang Endoscopy 50 (08), 751-760, 2018 | 212 | 2018 |
| Biliary repair and carcinogenesis are mediated by IL-33–dependent cholangiocyte proliferation J Li, N Razumilava, GJ Gores, S Walters, T Mizuochi, R Mourya, K Bessho, ... The Journal of clinical investigation 124 (7), 3241-3251, 2014 | 208 | 2014 |
| IL‐33 facilitates oncogene‐induced cholangiocarcinoma in mice by an interleukin‐6‐sensitive mechanism D Yamada, S Rizvi, N Razumilava, SF Bronk, JI Davila, MD Champion, ... Hepatology 61 (5), 1627-1642, 2015 | 138 | 2015 |
| Non-canonical Hedgehog signaling contributes to chemotaxis in cholangiocarcinoma N Razumilava, SA Gradilone, RL Smoot, JC Mertens, SF Bronk, AE Sirica, ... Journal of hepatology 60 (3), 599-605, 2014 | 94 | 2014 |
| A hedgehog survival pathway in ‘undead’lipotoxic hepatocytes K Kakisaka, SC Cazanave, NW Werneburg, N Razumilava, JC Mertens, ... Journal of hepatology 57 (4), 844-851, 2012 | 70 | 2012 |
| Notch and mTOR signaling pathways promote human gastric cancer cell proliferation ES Hibdon, N Razumilava, TM Keeley, G Wong, S Solanki, YM Shah, ... Neoplasia 21 (7), 702-712, 2019 | 68 | 2019 |
| Targeting PDGFR‐β in Cholangiocarcinoma CD Fingas, JC Mertens, N Razumilava, SF Bronk, AE Sirica, GJ Gores Liver International 32 (3), 400-409, 2012 | 56 | 2012 |
| Noncoding RNA in cholangiocarcinoma M Salati, C Braconi Seminars in liver disease 39 (01), 013-025, 2019 | 49 | 2019 |
| Polo‐like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma CD Fingas, JC Mertens, N Razumilava, S Sydor, SF Bronk, ... Hepatology 58 (4), 1362-1374, 2013 | 47 | 2013 |
| MiR130b from Schlafen4+ MDSCs stimulates epithelial proliferation and correlates with preneoplastic changes prior to gastric cancer L Ding, Q Li, J Chakrabarti, A Munoz, E Faure-Kumar, R Ocadiz-Ruiz, ... Gut 69 (10), 1750-1761, 2020 | 45 | 2020 |
| Hepatobiliary organoids and their applications for studies of liver health and disease: are we there yet? J Shiota, LC Samuelson, N Razumilava Hepatology 74 (4), 2251-2263, 2021 | 41 | 2021 |
| Notch-driven carcinogenesis: the merging of hepatocellular cancer and cholangiocarcinoma into a common molecular liver cancer subtype N Razumilava, GJ Gores Journal of hepatology 58 (6), 1244-1245, 2013 | 41 | 2013 |
| Liver toxicity with cancer checkpoint inhibitor therapy BA Nadeau, LA Fecher, SR Owens, N Razumilava Seminars in Liver Disease 38 (04), 366-378, 2018 | 40 | 2018 |
| Effectiveness and cost of radiofrequency ablation and stereotactic body radiotherapy for treatment of early‐stage hepatocellular carcinoma: an analysis of SEER‐Medicare ND Parikh, VD Marshall, M Green, TS Lawrence, N Razumilava, D Owen, ... Journal of medical imaging and radiation oncology 62 (5), 673-681, 2018 | 38 | 2018 |
